Emergency Info

Morrison | Foerster

Japan
Japan
China
China
Europe Israel
Hebrew
SEARCH

Europe Breadcrumb
Europe Overview - Left
Europe Practices & Industries left
Europe Attorney & Professionals
Europe Offices - Left
Europe Careers - Left
Europe Legal Updates & News Left
Europe Events - Left

Education
  • University of Hertfordshire (LL.B.,1994)
  • Nottingham Law School (L.P.C.,1995)


Bar Admissions
Admitted only in
  • England & Wales

Natalie Diep Natalie Diep

Partner
Primary Office: London

Email: ndiep@mofo.com
Phone: 44 20 7920 4070
Fax: +44 (0)20 7496 8500

Download vCard



Professional Summary



Natalie Diep is a partner in the London office of Morrison & Foerster and is a member of the Corporate Group. Ms. Diep advises on a wide range of corporate issues including equity offerings, private placements, IPO's and mergers and acquisitions.

Ms. Diep spent a number of years at Weil, Gotshal & Manges and joined Morrison & Foerster in 2005 having spent a year as Legal Counsel for the Equity Capital Markets department of Lehman Brothers.



Representative Matters
  • advising Piper Jaffray in its capacity as underwriter and placement agent for Antisoma plc in the acquisition of Xanthus Pharmaceuticals Inc. and related fundraising;
  • advising Acambis plc on its successful placing and open offer to raise £40 million;
  • advising Collins Stewart in its capacity as sponsor and underwriter for Northwest Biotherapeutics Inc. on its successful IPO and fundraising on AIM;
  • advising Amsterdam Molecular Therapeutics on its successful IPO on Euronext and related fundraising of €50 million;
  • advising Ardana on its successful placing and open offer to raise £11 million;
  • advising Silverjet plc on its successful IPO and further fundraisings on AIM;
  • advising Renovo Group plc on its successful IPO on the Official List and related Global Offering of £50 million;
  • advising Oxford Biomedica plc on a proposed placing and open offer and related investment by Sigma-Aldrich to raise £30.1 million;
  • advising ReNeuron Group plc on its successful IPO on AIM; and
  • advising Plethora Solutions plc on its successful IPO on AIM, and its subsequent fundraising in connection with its acquisition of Timm Medical.